Pfizer's chaotic year wraps up with plunging stock, grim guidance
Investors who own Pfizer Inc. NYSE: PFE may have expected 2023 to be what football teams call a "rebuilding year." The company shifted its focus away from COVID-19 drugs and toward potential deals,...
Pfizer: Buy The Panic
Pfizer stock has fallen 45% YTD as it has been impacted by the decline in revenue from COVID-19 products. The recent news about Danuglipron has added fuel to the fire. But is everything so bad when...
Pfizer Is Not Cheap, And The 5.7% Yield Is Not As Safe As You Might Think
Pfizer's stock reached an all-time high in 2021 due to high demand for its COVID-19 vaccine but has since declined by 45% year-to-date. The company has revised its financial guidance for FY24, expe...
Pfizer (PFE) Stock Rises on FDA Nod for Expanded Use of Padcev
The FDA approves Pfizer's (PFE) Padcev in combination with Merck's (MRK) Keytruda for adult patients with advanced bladder cancer. Stock rises 1.6%.
Why Pfizer Stock Is Bouncing Back
Pfizer issued weak guidance last week. Investors got spooked -- but today they're getting excited.
Pfizer (PFE) Beats Stock Market Upswing: What Investors Need to Know
The latest trading day saw Pfizer (PFE) settling at $27.06, representing a +1.61% change from its previous close.
Why Pfizer Stock Was a Winner on Monday
The healthcare giant won FDA approval for its cancer drug, to be used in combination with another treatment. Padcev earned the approval for the treatment of bladder cancer.
Pfizer Slashed Its Guidance, but Is It Still a Smart Long-Term Buy?
Pfizer just issued updated financial guidance, and it's not great. But its plans over the rest of this decade will likely turn things around.
Should You Worry About the Latest Wave of Bad News from Pfizer?
Pfizer just released 2024 earnings forecasts that fell short of analysts' estimates. Lower demand for coronavirus products is weighing on earnings and the stock price.
Pfizer: The Bears Have Won This Round
PFE has squandered the COVID-19 windfall by overpaying for Seagen, while contributing to the deterioration of its balance sheet and the eventual plunge in its stock prices. We believe that its inve...
Could Pfizer Stock Help You Become a Millionaire?
Pfizer doesn't have a great track record in the stock market over the past 20 years. However, the company has substantially revamped its business recently.
Pfizer: Dividend Boost At The Right Time
Pfizer, Inc. stock has fallen nearly 60% from its peak in December 2021. Could a turnaround be near? In a promising sign, Pfizer has announced its 14th consecutive annual dividend increase, signali...
Here's how much a $10k investment in Pfizer stock 5 years ago is now worth
For Pfizer (NYSE: PFE) investors, 2023 has been a tumultuous journey, marked by a nearly 50% decline in the stock – making it the drugmaker's worst-performing year on record.
Pfizer Helped Save the World With Covid Vaccines. Now It Needs to Right Itself.
The drugmaker is pulling back on some of its research programs and laying off workers after overestimating pandemic-product sales.
Pfizer increases dividend by one penny to 42 cents a share
Pfizer Inc. PFE, -1.99% said late Thursday that its board of directors declared an increase in the company's quarterly dividend to 42 cents a share, from 41 cents a share. The dividend is payable M...
Related Companies